NCT04865705 is a Phase 2 clinical trial of tislelizumab in Stage III, sponsored by West China Hospital.

Who is sponsoring NCT04865705?

NCT04865705 is sponsored by West China Hospital.

What drugs are being tested in NCT04865705?

Interventions in NCT04865705: tislelizumab.

What condition does NCT04865705 study?

NCT04865705 studies Stage III, Non-small Cell Lung Cancer.

Is NCT04865705 still recruiting?

NCT04865705 is currently status unknown. Last updated 29 April 2021.

Last reviewed 2021-04-29 · How we verify

NCT04865705

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer

Status unknown Phase 2 Last updated 29 April 2021

What this trial tests

Phase 2 trial testing tislelizumab in Stage III in 33 participants. Status unknown.

Timeline

10 November 2020

Primary endpoint
10 December 2021

10 June 2022

Quick facts

Lead sponsor	West China Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	10 November 2020
Primary completion	10 December 2021
Estimated completion	10 June 2022
Sites	1 location across China

Drugs / interventions tested

tislelizumab (TISLELIZUMAB) — full drug profile →

Conditions studied

Stage III — all drugs for Stage III →
Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

West China Hospital

Who can join

Adults 18 to 65, any sex, with Stage III or Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, one-arm, phase II study aimed at evaluating tislelizumab combined with platinum-containing dual-drug chemotherapy as a neoadjuvant treatment, supplemented with tislelizumab after surgery in patients with stage III non-small cell lung cancer.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives.
Godoy LA, Chen J, Ma W, Lally J, et al · · 2023 · cited 34× · PMID 36650586 · DOI 10.1186/s40364-022-00444-7
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer.
Qiu B, Cai K, Chen C, Chen J, et al · · 2021 · cited 17× · PMID 34733623 · DOI 10.21037/tlcr-21-634
Expert consensus on perioperative treatment for non-small cell lung cancer.
Duan J, Tan F, Bi N, Chen C, et al · · 2022 · cited 13× · PMID 35958323 · DOI 10.21037/tlcr-22-527
Efficacy, safety, and survival of neoadjuvant immunochemotherapy in operable non-small cell lung cancer: a systematic review and meta-analysis.
Zheng Y, Feng B, Chen J, You L. · · 2023 · cited 9× · PMID 38106421 · DOI 10.3389/fimmu.2023.1273220

Verify or expand the search:

Other trials of tislelizumab

Trials testing the same drug.

NCT07468071 — Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agen · Phase 1, PHASE2 · not yet recruiting
NCT07373990 — Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma · Phase 3 · not yet recruiting
NCT06749886 — An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1- · Phase 2 · recruiting
NCT06056804 — Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal · Phase 2 · active not recruiting
NCT06118658 — Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations · Phase 2 · not yet recruiting

Other West China Hospital trials

Trials by the same sponsor.

NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04865705 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West China Hospital
Last refreshed: 29 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04865705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing